Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 2

Conditions

Hematologic Neoplasms 2Neutropenia 1Neoplasms 1Febrile Neutropenia 1

Interventions

venetoclax 160Cytarabine 117Cyclophosphamide 111Specimen Handling 102Azacitidine 102fludarabine 91Biopsy 78Rituximab 51Methotrexate 45Daunorubicin 45fludarabine phosphate 41Vincristine 38Dexamethasone 37Decitabine 37Injections 36Magnetic Resonance Spectroscopy 35blinatumomab 33Granulocyte Colony-Stimulating Factor 33Mycophenolic Acid 30Idarubicin 30Whole-Body Irradiation 29ibrutinib 28Tacrolimus 27Busulfan 27Prednisone 26Etoposide 26Doxorubicin 26acalabrutinib 24Melphalan 24Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cefepime × Other hematologic neoplasm × 90 days × Clear all
NCT07590648 2026-05-15

E-STOP2

Hospital Universitari Vall d'Hebron Research Institute

Phase 4 Not yet recruiting
136 enrolled
Classical hematologyOther hematologic neoplasm

Neoplasms, Neutropenia, Hematologic Neoplasms, Febrile Neutropenia

NCT04983901 2026-04-06

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 38 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡